The improving strategies and applications of nanotechnology-based drugs in hepatocellular carcinoma treatment

被引:6
作者
Ren, Xiangyang [1 ]
Su, Danyang [1 ]
Shi, Doudou [2 ]
Xiang, Xiaohong [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] Ninth Hosp Xian, Xian, Shaanxi, Peoples R China
关键词
nanotechnology-based drugs; hepatocellular carcinoma; treatment; applications; improving strategies; DELIVERY SYSTEM; COMBINATION THERAPY; CANCER; NANOPARTICLES; SORAFENIB; NANOMEDICINE; LIVER; STABILITY; CHEMOTHERAPY; DEAMIDATION;
D O I
10.3389/fbioe.2023.1272850
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Hepatocellular carcinoma (HCC) is one of the leading causes of tumor-related death worldwide. Conventional treatments for HCC include drugs, radiation, and surgery. Despite the unremitting efforts of researchers, the curative effect of HCC has been greatly improved, but because HCC is often found in the middle and late stages, the curative effect is still not satisfactory, and the 5-year survival rate is still low. Nanomedicine is a potential subject, which has been applied to the treatment of HCC and has achieved promising results. Here, we summarized the factors affecting the efficacy of drugs in HCC treatment and the strategies for improving the efficacy of nanotechnology-based drugs in HCC, reviewed the recent applications' progress on nanotechnology-based drugs in HCC treatment, and discussed the future perspectives and challenges of nanotechnology-based drugs in HCC treatment.
引用
收藏
页数:14
相关论文
共 121 条
  • [1] pH and its applications in targeted drug delivery
    Abdella, Sadikalmahdi
    Abid, Fatima
    Youssef, Souha H.
    Kim, Sangseo
    Afinjuomo, Franklin
    Malinga, Constance
    Song, Yunmei
    Garg, Sanjay
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (01)
  • [2] Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma
    Abuduwaili, Weinire
    Wang, Xiang
    Huang, An-Tian
    Sun, Jia-Lei
    Xu, Ru-Chen
    Zhang, Guang-Cong
    Liu, Zhi-Yong
    Wang, Fu
    Zhu, Chang-Feng
    Liu, Tao-Tao
    Dong, Ling
    Zhu, Ji-Min
    Weng, Shu-Qiang
    Li, Yuhao
    Shen, Xi-Zhong
    [J]. ACS APPLIED MATERIALS & INTERFACES, 2022, 14 (33) : 37356 - 37368
  • [3] Protein-Encoding Free-Standing RNA Hydrogel for Sub-Compartmentalized Translation
    Ahn, So Yeon
    Kim, Jeonghun
    Vellampatti, Srivithya
    Oh, Sung
    Lim, Yong Taik
    Park, Sung Ha
    Luo, Dan
    Chung, Junho
    Um, Soong Ho
    [J]. ADVANCED MATERIALS, 2022, 34 (18)
  • [4] Aljabali Alaa A. A., 2022, Pharmaceutical Nanotechnology, V10, P257, DOI 10.2174/2211738510666220817120307
  • [5] Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
    Bao, Macus Hao-Ran
    Wong, Carmen Chak-Lui
    [J]. CELLS, 2021, 10 (07)
  • [6] Controlled Drug Release from Nanoengineered Polysaccharides
    Bayer, Ilker S.
    [J]. PHARMACEUTICS, 2023, 15 (05)
  • [7] Principles of nanoparticle design for overcoming biological barriers to drug delivery
    Blanco, Elvin
    Shen, Haifa
    Ferrari, Mauro
    [J]. NATURE BIOTECHNOLOGY, 2015, 33 (09) : 941 - 951
  • [8] Chavda Vivek P, 2023, Nanotheranostics, V7, P128, DOI 10.7150/ntno.80120
  • [9] PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
    Cheever, Martin A.
    Higano, Celestia S.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (11) : 3520 - 3526
  • [10] The use of RNA-based treatments in the field of cancer immunotherapy
    Chehelgerdi, Mohammad
    Chehelgerdi, Matin
    [J]. MOLECULAR CANCER, 2023, 22 (01)